SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-17-372069
Filing Date
2017-12-18
Accepted
2017-12-18 16:15:57
Documents
5
Period of Report
2017-12-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d513316d8k.htm 8-K 29694
2 EX-4.1 d513316dex41.htm EX-4.1 849440
3 EX-99.1 d513316dex991.htm EX-99.1 24378
4 GRAPHIC g513316snap1.jpg GRAPHIC 17515
5 GRAPHIC g513316snap2.jpg GRAPHIC 6886
  Complete submission text file 0001193125-17-372069.txt   938914
Mailing Address 2150 ST. ELZEAR BLVD. WEST LAVAL QUEBEC A8 H7L 4A8
Business Address 2150 ST. ELZEAR BLVD. WEST LAVAL QUEBEC A8 H7L 4A8 514-744-6792
Valeant Pharmaceuticals International, Inc. (Filer) CIK: 0000885590 (see all company filings)

IRS No.: 000000000 | State of Incorp.: NJ | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-14956 | Film No.: 171261559
SIC: 2834 Pharmaceutical Preparations